Golimumab

Golimumab
Monoclonal antibody
Type Whole antibody
Source Human
Target TNFα
Clinical data
Trade names Simponi
AHFS/Drugs.com monograph
MedlinePlus a610010
License data
Routes of
administration
Subcutaneous injection
Legal status
Legal status
Identifiers
CAS Number 476181-74-5 N
ATC code L04AB06 (WHO)
ChemSpider none
UNII 91X1KLU43E YesY
KEGG D04358 YesY
ChEMBL CHEMBL1201833 N
Chemical data
Formula C6530H10068N1752O2026S44
Molar mass 147 kg/mol
 NYesY (what is this?)  (verify)

Golimumab (CNTO 148)[1] is a human monoclonal antibody which is used as an immunosuppressive drug and marketed under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule[2] and hence is a TNF inhibitor.

Golimumab was developed by Centocor and is approved in Canada[3] and the United States[4] as a once monthly subcutaneous treatment for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.[5][6] Golimumab has been approved in 2013 for use in adults with moderately to severely active ulcerative colitis.

In the same year, Johnson & Johnson, the parent company of Centocor, also received an approval from European Medicines Agency (EMEA) for the use of golimumab as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.[7] Golimumab is marketed by Merck & Co, Inc. in Europe, pending final arbitration between J&J and Merck.[8][9][10]

Clinical trials

Rheumatoid arthritis

Large, double-blind randomized controlled trials in patients with rheumatoid arthritis have shown that golimumab in combination with methotrexate was more effective than methotrexate alone.[11]

References

  1. Mazumdar, Sohini; David Greenwald (2009). "Golimumab". mAbs 1 (5): 422–431. doi:10.4161/mabs.1.5.9286.
  2. Statement On A Nonproprietary Name Adopted By The USAN Council – Golimumab, American Medical Association.
  3. "Health Canada Approves Simponi (Golimumab) For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis". Apr 2009
  4. FDA Approves Simponi
  5. "FDA clears potential blockbuster arthritis drug". North County Times (Lee Enterprises). Associated Press. 24 April 2009. Retrieved 23 October 2010.
  6. Maxwell, LJ; Zochling, J; Boonen, A; Singh, JA; Veras, MM; Tanjong Ghogomu, E; Benkhalti Jandu, M; Tugwell, P; Wells, GA (18 April 2015). "TNF-alpha inhibitors for ankylosing spondylitis.". The Cochrane database of systematic reviews 4: CD005468. PMID 25887212.
  7. Johnson & Johnson Reports 2008 First-Quarter Results
  8. FDA approves Johnson & Johnson rheumatoid arthritis drug golimumab
  9. Merck sees fast ruling in J&J Remicade arbitration
  10. "Simponi European Public Assessment Report". European Medicines Agency. Retrieved 2009-11-15.
  11. Oldfield V, Plosker GL..Biodrugs 2009;23(2):125-135. doi:10.2165/00063030-200923020-00005.
This article is issued from Wikipedia - version of the Sunday, March 20, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.